1. Recent Developments in the Treatment of Advanced and Metastatic RCC

3. Introduction

4. CheckMate-214: Nivolumab + Ipilimumab

5. CheckMate-214: Results for Patients With Intermediate/Poor-Risk Disease[a,b]

6. CheckMate-214: Results for Patients With Favorable-Risk Disease

7. How Do You Treat?

8. Nivolumab/Ipilimumab in Patients With Disease With Sarcomatoid Features

9. Approval of Nivolumab/Ipilimumab in Europe

10. Checkpoint Inhibition + VEGF Inhibition

11. KEYNOTE-426: Pembrolizumab + Axitinib

12. KEYNOTE-426: Results

13. Pembrolizumab + Axitinib in Patients With Disease With Sarcomatoid Features

14. JAVELIN Renal 101: Avelumab + Axitinib

15. JAVELIN Renal 101: Results

16. IMmotion 151: Atezolizumab + Bevacizumab

17. Ongoing Phase 3 Trials in the First Line for Patients With Advanced RCC

18. Implications of These Results for Patients With Favorable-Risk Disease

19. Implications of These Results for Patients With Intermediate/Poor-Risk Disease

20. Complete Response Rate

21. Debulking Nephrectomy

22. Debulking Nephrectomy (cont)

23. Biomarkers

24. Second-Line Therapy

25. Concluding Remarks

26. Abbreviations

27. Abbreviations (cont)